Soonfast Completes Trial Production of Antiviral Medicine
Posted on: Wednesday, 17 October 2007, 12:00 CDT
China Biopharma has announced that its partner Soonfast Pharmaceuticals has successfully completed trial production of an antiviral product developed to treat infections from human papillomavirus and herpes simplex virus.
The all-natural medicine has been approved in China for external use to treat human papillomavirus and herpes simplex virus. Tests have shown an inhibitory effect on the growth of HPV and HSV, and the drug can reduce the infection from HPV and HSV by up to 90% in only two to three days, according to China Biopharma.
According to the agreement reached with Soonfast earlier this year, China Biopharma has the right to distribute the medicine in overseas markets.
China Biopharma plans to launch the drug in overseas markets including Europe and the US. The company and Soonfast also plan to jointly conduct studies on its extracts in both China and US so as to obtain the necessary approval for selling this medicine as an over-the-counter drug.
Source: Datamonitor
Related Articles
- China National Medicines Corporation Issues Milestone Purchase Order for 12,000 STA Systems
- China Biopharma, Inc. Issues Corporate Information Update
- Sinovac Receives China State Food and Drug Administration (SFDA) Approval for Pandemic Influenza H5N1 Vaccine
- China Biopharma Signs Marketing Agreement With Beijing Keyuan
- China Biopharma Reaches Agreement With a Regional Pharma to Launch New Pharmaceutical Products
- Currently China Has About 3,500 Drug Companies, Falling From More Than 5,000 in 2004, According To Government Figures
- China BioPharma Appoints Dr. Yimin Yu, Current Chairman of HYTE Research to Advisory Board
- Techedge Inc. Signs Definitive Agreement to Acquire China BioPharma Ltd.
- Techedge, Inc. Appoints Dr. Shu As CEO and Chief Scientist for China BioPharma
- Ludlow Capital Initiates Coverage on China BioPharma's Influenza Vaccine Research
 |
 |
User Comments (0)
RSS Feeds